Drugs / SY001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06562647 | Apr 2023 → Dec 2026 expected | cancer-related condition, ovarian carcinoma | Cell Origin Biotech (Hangzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06562647 ↗ |
| Route | Intravenous | “via intravenous injection” NCT06562647 ↗ |